Roquefort Therapeutics (LON:ROQ) Trading Up 16.1% – What’s Next?

Shares of Roquefort Therapeutics plc (LON:ROQ) shot up 16.1% on Monday . The stock traded as high as GBX 2.10 ($0.03) and last traded at GBX 2.09 ($0.03). 5,286,537 shares changed hands during mid-day trading, an increase of 71% from the average session volume of 3,088,488 shares. The stock had previously closed at GBX 1.80 ($0.02).

Roquefort Therapeutics Stock Performance

The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The stock has a market cap of £2.71 million, a PE ratio of -1.76 and a beta of 0.05. The business has a 50 day moving average price of GBX 2.74 and a two-hundred day moving average price of GBX 3.58.

Insider Buying and Selling at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Stephen Paul West purchased 400,000 shares of the stock in a transaction on Tuesday, February 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,600.62). 60.40% of the stock is currently owned by corporate insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.